Page 167 - 2018_11-Haematologica-web

Prognostic markers of double-/triple-hit lymphomas
ciated with survival. Blood. 2009;114(11):
2273–2279.
7. Pedersen MO, Gang AO, Poulsen TS, et al.
Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B- cell lymphoma: a single centre’s experience. Eur J Haematol. 2012;89(1):63–71.
8. Pedersen MO, Gang AO, Poulsen TS, et al. MYC translocation partner gene determines survival of patients with large B-cell lym- phoma with MYC- or double-hit MYC/BCL2 translocations. Eur J Haematol. 2014;92(1):42–48.
9. Aukema SM, Kreuz M, Kohler CW, et al; Molecular Mechanisms in Malignant Lymphomas Network Project. Biological characterization of adult MYC-transloca- tion-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica. 2014;99(4):726-735.
10. Bertrand P, Bastard C, Maingonnat C, et al. Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglob- ulin partners in B-cell lymphomas. Leukemia. 2007;21(3):515–523.
11. Li S, Saksena A, Desai P, et al. Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC/BCL2 double hit lym- phoma. Oncotarget. 2016;7(25):38122– 38132.
12. Clipson A, Barrans S, Zeng N, et al. The prog- nosis of MYC translocation positive diffuse large B-cell lymphoma depends on the sec- ond hit. J Pathol Clin Res. 2015;1(3):125–133.
13. Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354–2361.
14. Pillai RK, Sathanoori M, Van Oss SB, Swerdlow SH. Double-hit B-cell lym- phomas with BCL6 and MYC translocations are aggressive, frequently extranodal lym- phomas distinct from BCL2 double-hit B-cell lymphomas. Am J Surg Pathol. 2013;37(3): 323–332.
15. Li S, Desai P, Lin P, et al. MYC/BCL6 double- hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis. Histopathology. 2016;68(7): 1090–1098.
16. Kanungo A, Medeiros LJ, Abruzzo LV, Lin P. Lymphoid neoplasms associated with con- current t(14;18) and 8q24/c-MYC transloca- tion generally have a poor prognosis. Mod Pathol. 2006;19(1):25–33.
17. Le Gouill S, Talmant P, Touzeau C, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica. 2007;92(10):1335–1342.
18. Lin P, Medeiros LJ. High-grade B-cell lym- phoma/leukemia associated with t(14;18) and 8q24/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis. Haematologica. 2007;92 (10):1297–1301.
19. Niitsu N, Okamoto M, Miura I, Hirano M. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia. 2009;23(4):777–783.
20. Tomita N, Tokunaka M, Nakamura N, et al.
Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica. 2009;94(7):935–943.
21. Snuderl M, Kolman OK, Chen YB, et al. B- cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic fea- tures distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol. 2010;34(3):327–340.
22. Akyurek N, Uner A, Benekli M, Barista I. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with dif- fuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer. 2012;118(17):4173–4183.
23. Li S, Lin P, Fayad LE, et al. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germi- nal center B-cell immunophenotype and poor outcome. Mod Pathol. 2012;25(1):145–156.
24. Cohen JB, Geyer SM, Lozanski G, et al. Complete response to induction therapy in patients with MYC-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival. Cancer. 2014;120(11):1677–1685.
25. Oki Y, Noorani M, Lin P, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014;166(6):891–901.
26. Ye Q, Xu-Monette ZY, Tzankov A, et al. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Oncotarget. 2016;7(3):2401–2416.
27. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242.
28. Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008;26(16):2717–2724.
29. Mead GM, Barrans SL, Qian W, et al; UK National Cancer Research Institute Lymphoma Clinical Studies Group; Australasian Leukaemia Lymphoma Group. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophe- notypic criteria (MRC/NCRI LY10 trial). Blood. 2008;112(6):2248–2260.
30. Sun H, Savage KJ, Karsan A, et al. Outcome of patients with non-Hodgkin lymphomas with concurrent MYC and BCL2 rearrange- ments treated with CODOX-M/IVAC with rituximab followed by hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2015;15(6):341–348.
31. Cuccuini W, Briere J, Mounier N, et al. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplanta- tion. Blood. 2012;119(20):4619–4624.
32. Van Den Neste E, Schmitz N, Mounier N, et al. Outcomes of diffuse large B-cell lym-
phoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transplant. 2017;52(2):216–221.
33. Herrera AF, Mei M, Low L, et al. Relapsed or refractory double-expressor and double- hit lymphomas have inferior progression- free survival after autologous stem-cell transplantation. J Clin Oncol. 2017;35(1): 24–31.
34. Xu X, Zhang L, Wang Y, et al. Double-hit and triple-hit lymphomas arising from follic- ular lymphoma following acquisition of MYC: report of two cases and literature review. Int J Clin Exp Pathol. 2013;6(4):788– 794.
35. Novak AJ, Asmann YW, Maurer MJ, et al. Whole-exome analysis reveals novel somat- ic genomic alterations associated with out- come in immunochemotherapy-treated dif- fuse large B-cell lymphoma. Blood Cancer J. 2015;5:e346.
36. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classifica- tion of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282.
37. Remstein ED, Dogan A, Einerson RR, et al. The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America. Am J Surg Pathol. 2006;30(12):1546–1553.
38. Cataldo KA, Jalal SM, Law ME, et al. Detection of t(2;5) in anaplastic large cell lymphoma: comparison of immunohisto- chemical studies, FISH, and RT-PCR in paraffin-embedded tissue. Am J Surg Pathol. 1999;23(11):1386–1392.
39. Maurer MJ, Ghesquieres H, Jais JP, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in dif- fuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32(10):1066–1073.
40. Landsburg DJ, Falkiewicz MK, Maly J, et al. Outcomes of patients with double-hit lym- phoma who achieve first complete remis- sion. J Clin Oncol. 2017;35(20):2260–2267.
41. McClure RF, Remstein ED, Macon WR, et al. Adult B-cell lymphomas with Burkitt-like morphology are phenotypically and geno- typically heterogeneous with aggressive clinical behavior. Am J Surg Pathol. 2005;29(12):1652–1660.
42. Landsburg DJ, Nasta SD, Svoboda J, Morrissette JJ, Schuster SJ. ‘Double-hit’ cyto- genetic status may not be predicted by base- line clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients. Br J Haematol. 2014;166(3):369–374.
43. Moore EM, Aggarwal N, Surti U, Swerdlow SH. Further exploration of the complexities of large B-cell lymphomas with MYC abnor- malities and the importance of a blastoid morphology. Am J Surg Pathol. 2017;41(9): 1155–1166.
44. Tzankov A, Xu-Monette ZY, Gerhard M, et al. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lym- phoma patients treated with rituximab- CHOP. Mod Pathol. 2014;27(7):958–971.
haematologica | 2018; 103(11)
1907